1. AACR 2026: Revolution Medicines' KRAS Inhibitor RMC-6236 Posts Strong Clinical Data, Cementing Lead in Hot Oncology Race
The American Association for Cancer Research (AACR) annual meeting in San Diego is being dominated by promising new data for KRAS-targeting therapies, with Revolution Medicines' lead drug, RMC-6236, delivering another round of compelling results. The findings solidify the compound's position at the forefront of one of ...